Cancer survival among US whites and minorities: A SEER (Surveillance, Epidemiology, and End Results) Program population-based study

Archives of Internal Medicine

Volumn 162, Issue 17, 2002, Pages 1985-1993

  Clegg, Limin X ^a   Li, Frederick P ^a   Hankey, Benjamin F ^a   Chu, Kenneth ^a   Edwards, Brenda K ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; BRONCHUS CANCER; CANCER STATISTICS; CANCER SURVIVAL; CAUCASIAN; COLORECTAL CANCER; CONTROLLED STUDY; ETHNIC DIFFERENCE; FEMALE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MINORITY GROUP; NEGRO; PRIORITY JOURNAL; PROSTATE CANCER; RACE DIFFERENCE; SURVIVAL RATE;

AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; EUROPEAN CONTINENTAL ANCESTRY GROUP; EVIDENCE-BASED MEDICINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MINORITY GROUPS; NEOPLASM STAGING; NEOPLASMS; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; UNITED STATES;

EID: 0037163481     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.162.17.1985     Document Type: Article

References (52)

1. American Cancer Society. Cancer Facts and Figures 2001. Atlanta, Ga: American Cancer Society; 2002.
2. Ries LAG, Eisner MP, Kosary CL, et al. SEER Cancer Statistics Review, 1973-1997. Bethesda, Md: National Cancer Institute; 2000.
3. American Joint Committee on Cancer. AJCC Cancer Staging Manual. Philadelphia, Pa: Lippincott-Raven Publishers; 1998.
4. Cancer Statistics Branch, National Cancer Institute. SEER Extent of Disease. Bethesda, Md: National Cancer Institute; 1988.
5. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
6. Cox DR. Regression models and life tables. J R Stat Soc B. 1972;26:187-220.
7. Eley JW, Hill HA, Chen VW, et al. Racial differences in survival from breast cancer: results of the National Cancer Institute Black/White Cancer Survival Study. JAMA. 1994;272:947-954.
8. Yood MU, Johnson CC, Blount A, et al. Race and differences in breast cancer survival in a managed care population. J Natl Cancer Inst. 1999;91:1487-1491.
9. Ragland KE, Selvin S, Merrill DW. Black-white differences in stage-specific cancer survival: analysis of seven selected sites. Am J Epidemiol. 1991;133:672-682.
10. Optenberg SA, Thompson IM, Friedrichs P, Wojcik B, Stein CR, Kramer B. Race, treatment, and long-term survival from prostate cancer in an equal-access medical care delivery system. JAMA. 1995;274:1599-1605.
11. Hankey BF, Ries LAG, Edwards BK. The SEER Program: a national resource. Cancer Fpidemiol Biomarkers Prev. 1999;12:1117-1121.
12. Eddy EM. Screening for breast cancer. Ann Intern Med. 1989;111:389-399.
13. Kerlikowske K, Grady D, Rubin SM. Efficacy of screening mammography: a meta-analysis. JAMA. 1995;272:149-154.
14. National Center for Health Statistics. Health, United States, 1998 With Socioeconomic Status and Health Chartbook. Hyattsville, Md: National Center for Health Statistics; 1998.
15. Ries LAG, Kosary CL, Hankey BF, Miller BA, Clegg LX, Edwards BK. SEER Cancer Statistics Review, 1973-1996. Bethesda, Md: National Cancer Institute; 1999.
16. Mandelblatt J, Traxler M, Lakin P, Kanetsky PL, Thomas L, Chauhan P. Breast and cervical cancer screening of poor, elderly, black women: clinical results and implications. Am J Prev Med. 1993;9:133-138.
17. Wells BL, Horm JW. Stage at diagnosis in breast cancer: race and socioeconomic factors. Am J Public Health. 1992;82:1383-1385.
18. Gregorio D, Cummings K, Michalek A. Stage of disease, and survival among white and black women with breast cancer. Am J Public Health. 1983;73:590-593.
19. Ayanian JZ, Kohler BA, Abe T, Epstein AM. The relation between health insurance coverage and clinical outcomes among women with breast cancer. N Engl J Med. 1993;329:326-331.
20. McWhorter WP, Mayer WJ. Black/white differences in type of initial breast cancer treatment and implications for survival. Am J Public Health. 1987;77:1515-1517.
21. Bennett CL, Ferreira MR, Davis TC, Kaplan J, Weinberger M, Kuzel T. Relation between literacy, race, and stage of presentation among low-income patients with prostate cancer. J Clin Oncol. 1998;16:3101-3104.
22. Lannin DR, Mathews HF, Mitchell J, Swanson MS, Swanson FH, Edwards MS. Influence of socioeconomic and cultural factors on racial differences in late-stage presentation of breast cancer. JAMA. 1998;279:1801-1807.
23. Oritz A. Handbook of North American Indians: Southwest. Vol 9. Washington, DC: Smithsonian Institution; 1979:67-76.
24. Chen VW, Correa P, Kurman RJ, et al. Histological characteristics of breast carcinoma in blacks and whites. Cancer Epidemiol Biomarkers Prev. 1994;3: 127-135.
25. Blaszyk H, Vaughn CB, Hartmann A, et al. Novel pattern of p53 gene mutations in an American black cohort with high mortality from breast cancer. Lancet. 1994; 343:1195-1197.
26. Shiao YH, Chen VW, Scheer WD, Wu XC, Correa P. Racial disparity in the association of p53 gene alterations with breast cancer survival. Cancer Res. 1995; 55:1485-1490.
27. Le Marchand L. Ethnic variation in breast cancer survival: a review. Breast Cancer Res Treat. 1991;18(suppl 1):S119-S126.
28. Winawer SJ, Fletcher RH, Miller L. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology. 1997;112:594-642.
29. Smith RA, von Eschenbach AC, Wender R. American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. CA Cancer J Clin. 2001;51:38-75
30. US Preventive Services Task Force. Guide to Clinical Preventive Services. Baltimore, Md: Williams & Wilkins; 1996.
31. Mandel JS, Bond JH, Church TR. Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med. 1993;328:1365-1371.
32. Hardcastle JD, Chamberlain JO, Robinson MH. Randomised controlled trial of faecal-occult blood screening for colorectal cancer. Lancet. 1996;348:1472-1477.
33. Kronborg O, Fenger C, Olsen J. Randomised study of screening for colorectal cancer with faecal-occult blood test. Lancet. 1996;348:1467-1471.
34. Mandel JS, Church TR, Bond JH. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med. 2000;343:1603-1607.
35. Hankey BF, Feuer EJ, Clegg LX, et al. Cancer surveillance series: interpreting trends in prostate cancer, part 1: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst. 1999;91:1017-1024.
36. Carter HB, Pearson JD, Metter EJ. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA. 1992;267: 2215-2220.
37. Johansson JE, Holmberg L, Johansson S. Fifteen-year survival in prostate cancer: a prospective, population-based study in Sweden. JAMA. 1997;277: 467-471.
38. Whitmore WF. Localised prostatic cancer: management and detection issues. Lancet. 1994;343:1263-1267.
39. Chodak GW, Thisted RA, Gerber GS. Results of conservative management of clinically localized prostate cancer. N Engl J Med. 1994;330:242-248.
40. Fleming C, Wasson JH. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. JAMA. 1993;269:2650-2658.
41. Beck JR, Kattan MW, Miles BJ. A critique of the decision analysis for clinically localized prostate cancer. J Urol. 1994;152:1894-1899.
42. Patz EF Jr, Goodman PC, Bepler G. Screening for lung cancer. N Engl J Med. 2000;343:1627-1633.
43. Henschke CI, McCauley DI, Yankelevitz DF. Early lung cancer action project: overall design and findings from baseline screening. Lancet. 1999;354:99-105.
44. Welch HG, Schwartz LM, Woloshin S. Are increasing 5-year survival rates evidence of success against cancer? JAMA. 2000;283:2975-2978.
45. Ederer F, Axtell LM, Cutler SJ. The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr. 1961;6:101-121.
46. Percy C, Stanek E, Gloeckler L. Accuracy of cancer death certificates and its effect on cancer mortality statistics. Am J Public Health. 1981;71:242-250.
47. Lyman GH, Kuderer NM, Lyman SL, Cox CE, Reintgen D, Baekey P. Importance of race on breast cancer survival. Ann Surg Oncol. 1997;4:80-87.
48. Simon MS, Severson RK. Racial differences in survival of female breast cancer in the Detroit metropolitan area Cancer. 1996;77:308-314.
49. Simon MS, Severson RK. Racial differences in breast cancer survival: the interaction of socioeconomic status and tumor biology. Am J Obstet GynecoL 1997; 176:S233-S239.
50. Greenwald HP, Polissar NL, Dayal HH. Race, socioeconomic status and survival in three female cancers. Ethn Health. 1996;1:65-75.
51. Natarajan N, Nemoto D, Nemoto T, Mettlin C. Breast cancer survival among Orientals and whites living in the United States. J Surg Oncol. 1988;39:206-209.
52. Robbins AS, Whittemore AS, Van Den Eeden SK. Race, prostate cancer survival, and membership in a large health maintenance organization. J Natl Cancer Inst. 1998;90:986-990.